Literature DB >> 20070787

Pregnenolone, dehydroepiandrosterone, and schizophrenia: alterations and clinical trials.

Michael S Ritsner1.   

Abstract

Neurosteroids, such as pregnenolone (PREG), dehydroepiandrosterone (DHEA), and their sulfates (PREGS and DHEAS) are reported to have a modulatory effect on neuronal excitability and synaptic plasticity. They also have many other functions associated with neuroprotection, response to stress, mood regulation, and cognitive performance. Furthermore, these neurosteroids have been linked to, and their levels are altered in, neuropsychiatric disorders. This review highlights what is currently known about the metabolism and mode of action of PREG and DHEA, as well as about alterations of these neurosteroids in schizophrenia. This review also provides substantial information about clinical trials with DHEA and PREG augmentation with of antipsychotic agents in schizophrenia.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20070787      PMCID： PMC6493915          DOI： 10.1111/j.1755-5949.2009.00118.x

Source DB:  PubMed          Journal:  CNS Neurosci Ther        ISSN： 1755-5930            Impact factor:   5.243


  80 in total

1.  Pregnenolone protects mouse hippocampal (HT-22) cells against glutamate and amyloid beta protein toxicity.

Authors:  E Gursoy; A Cardounel; M Kalimi
Journal:  Neurochem Res       Date:  2001-01       Impact factor: 3.996

2.  Dehydroepiandrosterone replacement in women with adrenal insufficiency.

Authors:  W Arlt; F Callies; J C van Vlijmen; I Koehler; M Reincke; M Bidlingmaier; D Huebler; M Oettel; M Ernst; H M Schulte; B Allolio
Journal:  N Engl J Med       Date:  1999-09-30       Impact factor: 91.245

3.  Dehydroepiandrosterone (DHEA) protects hippocampal cells from oxidative stress-induced damage.

Authors:  S Bastianetto; C Ramassamy; J Poirier; R Quirion
Journal:  Brain Res Mol Brain Res       Date:  1999-03-20

Review 4.  Preclinical development of neurosteroids as neuroprotective agents for the treatment of neurodegenerative diseases.

Authors:  P A Lapchak; D M Araujo
Journal:  Int Rev Neurobiol       Date:  2001       Impact factor: 3.230

5.  Anti-stress effects of dehydroepiandrosterone: protection of rats against repeated immobilization stress-induced weight loss, glucocorticoid receptor production, and lipid peroxidation.

Authors:  Y Hu; A Cardounel; E Gursoy; P Anderson; M Kalimi
Journal:  Biochem Pharmacol       Date:  2000-04-01       Impact factor: 5.858

6.  Dehydroepiandrosterone sulfate and psychiatric measures in a frail, elderly residential care population.

Authors:  M F Morrison; E Redei; T TenHave; P Parmelee; A A Boyce; P S Sinha; I R Katz
Journal:  Biol Psychiatry       Date:  2000-01-15       Impact factor: 13.382

7.  Dehydroepiandrosterone protects hippocampal neurons against neurotoxin-induced cell death: mechanism of action.

Authors:  A Cardounel; W Regelson; M Kalimi
Journal:  Proc Soc Exp Biol Med       Date:  1999-11

8.  Neuroactive steroid levels in patients with generalized anxiety disorder.

Authors:  T Semeniuk; G S Jhangri; J M Le Mellédo
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2001       Impact factor: 2.198

9.  Dehydroepiandrosterone prevents oxidative injury induced by transient ischemia/reperfusion in the brain of diabetic rats.

Authors:  M Aragno; S Parola; E Brignardello; A Mauro; E Tamagno; R Manti; O Danni; G Boccuzzi
Journal:  Diabetes       Date:  2000-11       Impact factor: 9.461

10.  Dehydroepiandrosterone antagonizes the neurotoxic effects of corticosterone and translocation of stress-activated protein kinase 3 in hippocampal primary cultures.

Authors:  V G Kimonides; M G Spillantini; M V Sofroniew; J W Fawcett; J Herbert
Journal:  Neuroscience       Date:  1999-03       Impact factor: 3.590
View more
  8 in total

Review 1.  From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment.

Authors:  Bita Moghaddam; Daniel Javitt
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

Review 2.  Sex differences in schizophrenia, bipolar disorder, and post-traumatic stress disorder: Are gonadal hormones the link?

Authors:  Andrea Gogos; Luke J Ney; Natasha Seymour; Tamsyn E Van Rheenen; Kim L Felmingham
Journal:  Br J Pharmacol       Date:  2019-03-14       Impact factor: 8.739

Review 3.  Neurobehavioural complications of sleep deprivation: Shedding light on the emerging role of neuroactive steroids.

Authors:  Roberto Frau; Francesco Traccis; Marco Bortolato
Journal:  J Neuroendocrinol       Date:  2019-09-30       Impact factor: 3.627

4.  Targeting the Immune System with Pharmacotherapy in Schizophrenia.

Authors:  Jennifer K Melbourne; Benjamin Feiner; Cherise Rosen; Rajiv P Sharma
Journal:  Curr Treat Options Psychiatry       Date:  2017-04-18

5.  Human-like adrenal development in wild chimpanzees: A longitudinal study of urinary dehydroepiandrosterone-sulfate and cortisol.

Authors:  Kris H Sabbi; Martin N Muller; Zarin P Machanda; Emily Otali; Stephanie A Fox; Richard W Wrangham; Melissa Emery Thompson
Journal:  Am J Primatol       Date:  2019-11-10       Impact factor: 3.014

6.  Association between Serum Cortisol and DHEA-S Levels and Response to Antipsychotic Treatment in Schizophrenia.

Authors:  Zoja Babinkostova; Branislav Stefanovski; Danijela Janicevic-Ivanovska; Valentina Samardziska
Journal:  Open Access Maced J Med Sci       Date:  2015-02-22

7.  Increased serum dehydroepiandrosterone sulfate in the first episode but not in subsequent episodes in male patients with schizophrenia.

Authors:  Murat Beyazyüz; Yakup Albayrak; Elmas Beyazyüz; Cüneyt Unsal; Erol Göka
Journal:  Neuropsychiatr Dis Treat       Date:  2014-04-29       Impact factor: 2.570

8.  Natural Medicines for Psychotic Disorders: A Systematic Review.

Authors:  H J Rogier Hoenders; Agna A Bartels-Velthuis; Nina K Vollbehr; Richard Bruggeman; Henderikus Knegtering; Joop T V M de Jong
Journal:  J Nerv Ment Dis       Date:  2018-02       Impact factor: 2.254
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.